

Cover Story
NCI
By Matthew Bin Han Ong
The pace of innovation in oncology has made U.S. cancer researchers prime targets for foreign state-sponsored programs aimed at diverting intellectual property.
By Matthew Bin Han Ong
In Brief


Funding Opportunities
Clinical Roundup


Drugs & Targets


Trending Stories
- Two lawsuits vs. Tempus raise questions about privacy of germline data in cancer RWE
“Deidentified” ≠ “deidentifiable” - Mail-out colorectal cancer screening programs extend, rather than replace, clinical care
- Lou Weiner to step down as director of Georgetown’s Lombardi CCC after 18 years
- After a year, Stephenson institute sees a broader role in funding pancreatic cancer research, fostering collaborations
“We are not just funding research. We are building a trusted community.” - Trump administration announces “major crackdown” on healthcare fraud
- FDA issues draft guidance on accelerating development of individualized therapies for ultra-rare diseases














